|
|
Article: NGX-4010 and postherpetic neuralgia.(PIPELINE PREVIEWS)(NeurogesX, Inc introduced new synthetic capsaicin)(Brief article)
- Article from:
- Journal of Drugs in Dermatology
- Article date:
- November 1, 2007
- Author:
CopyrightCOPYRIGHT 2007 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NeurogesX, Inc recently announced positive results from its second phase III clinical trial for NGX-4010 in the treatment of postherpetic neuralgia. NGX-4010 is a non-narcotic, locally-acting dermal patch that contains synthetic capsaicin. The capsaicin is absorbed into the skin without being significantly absorbed into the bloodstream. It has been shown to lead to a clinically relevant reduction in peripheral pain associated with postherpetic neuralgia for up to 12 weeks after administration.
This second phase III trial was a multicenter, double-blind, controlled study that met its primary endpoint of reducing pain. During the ...
Related newspaper, magazine, and journal articles:
|
|
Article: NeurogesX Completes Enrollment in Pivotal Phase 3 ...
Business Wire;
June 13, 2006 ;
700+ words
... ... drug Transacin(TM) (NGX-4010) in patients suffering from postherpetic neuralgia (PHN). Transacin ... About Transacin (NGX-4010) Transacin is ... in mid 2006. About Postherpetic Neuralgia Postherpetic neuralgia ...
|
|